BRAF V600E状态显著区分甲状腺乳头状癌淋巴结转移相关死亡风险
本研究回顾性分析6国11中心2638例PTC患者,中位随访58个月,发现淋巴结转移相关死亡风险在BRAF V600E突变型与野生型间差异显著。在经典型PTC中,野生型BRAF患者LNM不增加死亡风险,而BRAF V600E突变患者LNM显著增加死亡风险。
要点
- 经典型PTC中,BRAF野生型患者LNM不增加死亡风险,突变型则显著增加。
- BRAF V600E合并LNM较两者均无者死亡风险大幅升高,HR达27.39。
- BRAF状态可用于区分LNM相关死亡风险,指导临床决策。
核心结论
- LNM相关死亡风险在PTC中由BRAF状态显著区分,经典型PTC中野生型BRAF无风险增加而突变型风险显著增加。
研究设计与样本
- 回顾性分析6国11中心2638例PTC患者(女性2015例,男性623例),中位年龄46岁,中位随访58个月。
主要发现
- 总体LNM在BRAF野生型患者中死亡风险 modest,在BRAF V600E患者中风险强。
- 经典型PTC野生型BRAF患者非LNM vs LNM死亡率0.3%(2/659) vs 1.2%(4/321),P=0.094,HR 4.37(95%CI 0.80-23.89),多因素调整后HR 3.32(95%CI 0.52-21.14)。
- 经典型PTC BRAF V600E患者非LNM vs LNM死亡率1.4%(7/515) vs 7.7%(28/363),P<0.001,HR 4.90(95%CI 2.12-11.29),多因素调整后HR 5.76(95%CI 2.19-15.11)。
- 共存LNM和BRAF V600E vs 两者均无的调整死亡HR为27.39(95%CI 5.15-145.80),Kaplan-Meier分析显示类似协同作用。
临床怎么用
- 临床可利用BRAF V600E状态区分PTC患者LNM相关死亡风险,突变型合并LNM者风险极高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. OBJECTIVE: To study whether BRAF V600E affected LNM-associated mortality in PTC. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively analyzed the effect of LNM on PTC-specific mortality with respect to BRAF status in 2638 patients (2015 females and 623 males) from 11 centers in 6 countries, with median age of 46 [interquartile range (IQR) 35-58] years and median follow-up time of 58 (IQR 26-107) months. RESULTS: Overall, LNM showed a modest mortality risk in wild-type BRAF patients but a strong one in BRAF V600E patients. In conventional PTC (CPTC), LNM showed no increased mortality risk in wild-type BRAF patients but a robustly increased one in BRAF V600E patients; mortality rates were 2/659 (0.3%) vs 4/321 (1.2%) in non-LNM vs LNM patients (P = 0.094) with wild-type BRAF, corresponding to a hazard ratio (HR) (95% CI) of 4.37 (0.80-23.89), which remained insignificant at 3.32 (0.52-21.14) after multivariate adjustment. In BRAF V600E CPTC, morality rates were 7/515 (1.4%) vs 28/363 (7.7%) in non-LNM vs LNM patients (P < 0.001), corresponding to an HR of 4.90 (2.12-11.29) or, after multivariate adjustment, 5.76 (2.19-15.11). Adjusted mortality HR of coexisting LNM and BRAF V600E vs absence of both was 27.39 (5.15-145.80), with Kaplan-Meier analyses showing a similar synergism. CONCLUSIONS: LNM-associated mortality risk is sharply differentiated by the BRAF status in PTC; in CPTC, LNM showed no increased mortality risk with wild-type BRAF but a robust one with BRAF mutation. These results have strong clinical relevance.
引用
- Tao Y, Wang F, Shen X, et al. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2021. PMID: 34273152. doi:10.1210/clinem/dgab286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。